|
Inclusion Criteria
|
|
Age 18 or older
|
|
Willing and able to give informed consent
|
|
Diagnosed with CML in chronic phase and have either the b3a2 (e14a2) or b2a2 (e13a2) variants that give rise to the p210 BCR-ABL protein
|
|
Currently taking imatinib, dasatinib, nilotinib or bosutinib
|
|
Has been on TKI therapy for at least 3 years
|
|
Documented BCR-ABL < 0.01% or undetectable BCR-ABL by RQ-PCR for at least 2 years according to the patient’s local lab
|
|
Documented BCR-ABL < 0.01% or undetectable BCR-ABL by RQ-PCR at least 3 times prior to screening according to the patient’s local lab
|
|
Two (2) Screening PCRs have been completed and both results are < 0.01% (better than MR4, i.e,. > 4 log reduction) by central lab
|
|
Has been on any number of TKIs, but has not been resistant to any TKI (changes made for intolerance are allowed)
|
|
Has been compliant with therapy per treating physician
|
|
Exclusion Criteria
|
|
Prior hematopoietic stem cell transplantation
|
|
Poor compliance with taking TKI
|
|
Unable to comply with lab appointments schedule and PRO assessments
|
|
Life expectancy less than 36 months
|
|
Resistant to previous TKI therapy
|
|
Pregnant or lactating women
|
